CN102858769A - 吡唑并吡啶激酶抑制剂 - Google Patents

吡唑并吡啶激酶抑制剂 Download PDF

Info

Publication number
CN102858769A
CN102858769A CN2011800130461A CN201180013046A CN102858769A CN 102858769 A CN102858769 A CN 102858769A CN 2011800130461 A CN2011800130461 A CN 2011800130461A CN 201180013046 A CN201180013046 A CN 201180013046A CN 102858769 A CN102858769 A CN 102858769A
Authority
CN
China
Prior art keywords
independently
compound
another
alkyl
optional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800130461A
Other languages
English (en)
Chinese (zh)
Inventor
J-M·希门尼斯
J·M·C·戈雷克
L·塞蒂莫
D·弗雷斯
G·布伦奇利
D·博亚尔
H·特温
S·杨
A·W·米勒
C·J·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN102858769A publication Critical patent/CN102858769A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800130461A 2010-01-27 2011-01-26 吡唑并吡啶激酶抑制剂 Pending CN102858769A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29864910P 2010-01-27 2010-01-27
US61/298,649 2010-01-27
US41042610P 2010-11-05 2010-11-05
US61/410,426 2010-11-05
PCT/US2011/022522 WO2011094273A1 (en) 2010-01-27 2011-01-26 Pyrazolopyridine kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102858769A true CN102858769A (zh) 2013-01-02

Family

ID=44088992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800130461A Pending CN102858769A (zh) 2010-01-27 2011-01-26 吡唑并吡啶激酶抑制剂

Country Status (9)

Country Link
US (1) US9067932B2 (enExample)
EP (1) EP2528917B1 (enExample)
JP (1) JP5769733B2 (enExample)
CN (1) CN102858769A (enExample)
AR (1) AR080856A1 (enExample)
AU (1) AU2011209726A1 (enExample)
CA (1) CA2787315A1 (enExample)
MX (1) MX2012008644A (enExample)
WO (1) WO2011094273A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764513A (zh) * 2013-09-18 2016-07-13 堪培拉大学 干细胞调控ii
CN107106517A (zh) * 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途
CN118923682A (zh) * 2024-07-22 2024-11-12 中国农业大学 一种化合物作为病原真菌Pmk1的抑制剂的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
EP2582702A1 (en) * 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
MX2012008642A (es) * 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CN111587120A (zh) * 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938303A (zh) * 2004-03-30 2007-03-28 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
WO2009073300A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2010011772A2 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853898A (en) 1971-07-20 1974-12-10 Sandoz Ag 3-(2-substituted amino) pyridyl-phenyl ketone imines
US4988705A (en) 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
FR2601015B1 (fr) 1986-07-04 1988-08-05 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US5100768A (en) 1989-05-09 1992-03-31 Kabushiki Kaisha Toshiba Photosensitive composition
JPH03206450A (ja) 1990-01-09 1991-09-09 Fuji Photo Film Co Ltd 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
JPH05331163A (ja) 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
UA44220C2 (uk) 1991-11-07 2002-02-15 Агрево Юк Лімітед Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами
US5476750A (en) 1992-12-29 1995-12-19 Hoechst Celanese Corporation Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists
DE69404306T2 (de) 1993-05-28 1997-10-30 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO1996006843A1 (en) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US5646330A (en) 1995-02-17 1997-07-08 Ciba-Geigy Corporation Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL132391A0 (en) 1997-04-18 2001-03-19 Kissei Pharmaceutical Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells
WO1998057957A1 (en) 1997-06-18 1998-12-23 Nissan Chemical Industries, Ltd. Pyridine compounds and herbicides
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
AU2001257490A1 (en) 2000-05-02 2001-11-12 Newbiotics, Inc. Improved beta-lactam antibiotics
AR029289A1 (es) 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
DE10035908A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
GB2373245A (en) 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CN102503903A (zh) 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
EP1601664B1 (en) 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US20050203067A1 (en) 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
CN101061101B (zh) 2003-12-22 2011-09-07 巴斯利尔药物股份公司 芳酰基呋喃和芳酰基噻吩
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1751119A1 (en) 2004-05-19 2007-02-14 AstraZeneca AB Novel fused heterocycles and uses thereof
US7452993B2 (en) * 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JPWO2006016548A1 (ja) 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
ATE554087T1 (de) 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
AU2005309566A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ES2345997T3 (es) 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
JP5180816B2 (ja) 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
JP4946728B2 (ja) 2007-08-23 2012-06-06 三菱電機株式会社 電力増幅器
MX2011000837A (es) * 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
US8569337B2 (en) * 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011762A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2012008642A (es) * 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938303A (zh) * 2004-03-30 2007-03-28 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
WO2009073300A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2010011772A2 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764513A (zh) * 2013-09-18 2016-07-13 堪培拉大学 干细胞调控ii
CN107106517A (zh) * 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途
CN118923682A (zh) * 2024-07-22 2024-11-12 中国农业大学 一种化合物作为病原真菌Pmk1的抑制剂的应用
CN118923682B (zh) * 2024-07-22 2025-09-05 中国农业大学 一种化合物作为病原真菌Pmk1的抑制剂的应用

Also Published As

Publication number Publication date
AR080856A1 (es) 2012-05-16
WO2011094273A1 (en) 2011-08-04
JP5769733B2 (ja) 2015-08-26
US20120071494A1 (en) 2012-03-22
EP2528917B1 (en) 2016-10-19
AU2011209726A1 (en) 2012-08-09
US9067932B2 (en) 2015-06-30
JP2013518111A (ja) 2013-05-20
EP2528917A1 (en) 2012-12-05
CA2787315A1 (en) 2011-08-04
MX2012008644A (es) 2012-11-23

Similar Documents

Publication Publication Date Title
JP6898914B2 (ja) コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤
JP6639497B2 (ja) ブロモドメインインヒビターおよびその使用
AU2016282289B2 (en) HPK1 inhibitors and methods of using same
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
JP6186434B2 (ja) 窒素複素環誘導体及びその医薬品への応用
JP6117238B2 (ja) ブロモドメイン阻害薬
KR20210100155A (ko) Ret 억제제, 이의 약학 조성물 및 용도
CN102459259A (zh) 吡唑并吡啶类
KR102589213B1 (ko) 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
CN102131809A (zh) 三环吡唑并吡啶激酶抑制剂
KR20140071361A (ko) 피라졸로[3,4-c]피리딘 화합물 및 사용 방법
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
CA2935867A1 (en) Heteroaryls and uses thereof
JP2018510851A (ja) 治療用ピリダジン化合物およびその使用
JP2011502994A (ja) タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体
TW201018680A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
JP2019504901A (ja) ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター
CN102471342A (zh) 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
KR20200027992A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
JP5769733B2 (ja) ピラゾロピリジンキナーゼ阻害剤
CA3193913A1 (en) Mrgx2 antagonists
KR102206321B1 (ko) 6,7,8,9-테트라하이드로-5H-피리도[2,3-d]아제핀 도파민 D3 리간드
JP2022515309A (ja) 置換アリール化合物、その製造方法及び用途
CN103003273A (zh) 吡唑并吡啶激酶抑制剂
CN102869664A (zh) 吡唑并嘧啶类激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179265

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130102